KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Bio-Rad Laboratories (BIO) over the last 17 years, with Q4 2025 value amounting to $3.3 million.

  • Bio-Rad Laboratories' Cash from Financing Activities rose 11259.54% to $3.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$283.2 million, marking a year-over-year decrease of 2943.33%. This contributed to the annual value of -$283.2 million for FY2025, which is 2943.33% down from last year.
  • Per Bio-Rad Laboratories' latest filing, its Cash from Financing Activities stood at $3.3 million for Q4 2025, which was up 11259.54% from -$52.5 million recorded in Q3 2025.
  • Over the past 5 years, Bio-Rad Laboratories' Cash from Financing Activities peaked at $1.2 billion during Q1 2022, and registered a low of -$202.7 million during Q2 2023.
  • In the last 5 years, Bio-Rad Laboratories' Cash from Financing Activities had a median value of -$47.3 million in 2021 and averaged -$496263.2.
  • Examining YoY changes over the last 5 years, Bio-Rad Laboratories' Cash from Financing Activities showed a top increase of 261397.77% in 2022 and a maximum decrease of 433476.44% in 2022.
  • Bio-Rad Laboratories' Cash from Financing Activities (Quarter) stood at $4.6 million in 2021, then plummeted by 1968.28% to -$86.6 million in 2022, then plummeted by 131.62% to -$200.6 million in 2023, then soared by 86.94% to -$26.2 million in 2024, then skyrocketed by 112.6% to $3.3 million in 2025.
  • Its Cash from Financing Activities was $3.3 million in Q4 2025, compared to -$52.5 million in Q3 2025 and -$136.3 million in Q2 2025.